Upcoming EventsMore >>
DateTitle
04/21/15
2:00 p.m. PT
Q1 2015 Amgen Earnings Conference Call
Recent NewsMore >>
DateTitle 
04/16/15Amgen Announces Webcast Of 2015 First Quarter Financial Results
THOUSAND OAKS, Calif., April 16, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will report its first quarter financial results on Tuesday, April 21, 2015, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. Live audio of the con... 
Printer Friendly Version
04/15/15FDA Approves Corlanor® (ivabradine) To Reduce The Risk Of Hospitalization For Worsening Heart Failure In Patients With Chronic Heart Failure
Corlanor is the First New Chronic Heart Failure Medicine Approved by the FDA in Nearly a Decade THOUSAND OAKS, Calif., April 15, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of Corlanor® (ivabradine), an oral medication indicated to reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction (LVEF) ≤35 percen... 
Printer Friendly Version
04/06/15European Commission Approves Amgen's Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Metastatic Colorectal Cancer
Important Step Towards Increasing Treatment Options for Patients With This Serious Disease THOUSAND OAKS, Calif., April 6, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the European Commission approved a new use of Vectibix® (panitumumab) as first-line treatment in combination with FOLFIRI for the treatment of adult patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC). About half of the patients with mCRC have WT RAS tumors.1  FOLFIRI, an irinotecan-based ch... 
Printer Friendly Version
03/30/15Amgen To Present At The Goldman Sachs Key Debates In Biosimilars Conference
THOUSAND OAKS, Calif., March 30, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Goldman Sachs Key Debates in Biosimilars conference at 9:05 a.m. ET on Thursday, April 2, 2015, at the Goldman Sachs Conference Center in New York City. Scott Foraker, vice president and general manager of biosimilars at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webca... 
Printer Friendly Version
What's New
04/02/15
Download Documentation Goldman Sachs Key Debates in Biosimilars Presentation
03/26/15
Download Documentation 2014 Annual Report and 10-K
03/23/15
Download Documentation AAD Presentation
03/16/15
Download Documentation ACC Presentation
03/04/15
Download Documentation 2010 – 2014 EPS Reconciliation
03/02/15
Download Documentation Cowen Healthcare Conference Presentation
02/04/15
Download Documentation Investor Insights Newsletter - Q4 2014
01/27/15
Download Documentation Q4 2014 Financial Results
01/27/15
Download Documentation Q4 2014 Amgen Earnings Conference Call Presentation
01/13/15
Download Documentation J.P. Morgan Healthcare Conference Presentation
Investor Insights Newsletters
DateTitle
02/04/15
Download Documentation Investor Insights Newsletter - Q4 2014
11/07/14
Download Documentation Investor Insights Newsletter - Q3 2014
08/07/14
Download Documentation Investor Insights Newsletter - Q2 2014
04/30/14
Download Documentation Investor Insights Newsletter - Q1 2014
02/11/14
Download Documentation Investor Insights Newsletter - Q4 2013
10/31/13
Download Documentation Investor Insights Newsletter - Q3 2013

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.